Victoria Johnson

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

Investigators noted that a formal independent validation cohort needs to be developed to realize the full potential of the human model.

The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation after reviewing the phase 1 safety and efficacy data.

The FDA and the European Medicines Agency have accepted marketing authorization applications and decisions are pending.

Excision BioTherapeutics has so far released positive safety data from the first 3 participants living with HIV-1, with no evidence of vector shedding in sexual organ tissue.

The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis.

Updated findings from a phase 1/2 trial of stem-cell derived islet cell therapy for type 1 diabetes (T1D) showed improved glycemic control and a reduction in insulin dependence.

Clinicians and nurses who treat patients with hemophilia with a gene therapy identified important factors and considerations needed in a potential shared decision making tool.